Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 16Unknown 3Terminated 3Active not recruiting 3Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 15Carcinoma, Non-Small-Cell Lung 6Neoplasms 4Uveal Melanoma 3Sarcoma 3Prostatic Neoplasms 3Neoplasm Metastasis 3Pancreatic Neoplasms 2Lung Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Brain Neoplasms 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous-Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Diseases 1Osteosarcoma 1Neoplastic Cells, Circulating 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Nasopharyngeal Carcinoma 1Metastatic Microsatellite Stable Colorectal Cancer 1Kidney Neoplasms 1Hypoxia 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1

Interventions

Ipilimumab 3Triamcinolone Acetonide 2Ranibizumab 2Nivolumab 2Amplified Fragment Length Polymorphism Analysis 2treosulfan 1salicylhydroxamic acid 1aldesleukin 1Ultrasonography 1Tramadol 1Temozolomide 1Tamoxifen 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Sorafenib 1Rose Bengal 1Radiosurgery 1Physical Examination 1Pharmacogenomic Testing 1Interviews as Topic 1Immunotherapy 1Ibuprofen 1Gemcitabine 1Eye Enucleation 1Cyclophosphamide 1Cisplatin 1Chemotherapy, Adjuvant 1CTLA-4 Antigen 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Uveal Melanoma × Ipilimumab × Clear all
NCT03068624 2024-01-25

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

M.D. Anderson Cancer Center

Phase 1 Unknown
34 enrolled
Dermatologic

Uveal Melanoma

NCT03528408 2023-04-11

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Hoosier Cancer Research Network

Phase 2 Unknown
52 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT02913417 2021-04-19

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

California Pacific Medical Center Research Institute

Phase 1/2 Unknown
26 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡